• The American College of Obstetricians and Gynecologists (ACOG) Guidelines for dealing with opioid use disorder in the pregnant/breastfeeding population highlights:
    • Screening for substance abuse should be a part of comprehensive obstetric care and should be done with validated screening tools such as:
      • NIDA Quick Screen (PDF).
      • For pregnant women with an opioid use disorder, opioid agonist therapy is the recommended therapy and is preferable to medically supervised withdrawal. Withdrawal is associated with high relapse rates, which can lead to worse outcomes.
    • Breastfeeding should be encouraged in women who are stable on their opioid agonists, who are not using illicit drugs, and who have no other contraindications, such as human immunodeficiency virus (HIV) infection. Women should be counseled about the need to suspend breastfeeding in the event of a relapse.
    • Access to adequate postpartum psychosocial support services, including substance use disorder treatment and relapse prevention programs, should be made available.
  • Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants (2MB, 165 pages, PDF).
  • For consultations about these special populations, please consider referring to the MotherToBaby.org specialists at (888) 285-3410.

What opioid agonist medications can be used in the pregnant/breastfeeding population?

View full ACOG guidelines for an in-depth explanation of recommendations.